Compare Illumina, Inc. (ILMN) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Block Inc — how do they compare? Illumina, Inc. trades at $275.39 (market cap $39.95B), while Block Inc trades at $77.16 (market cap $45.20B). The key difference: Illumina, Inc. and Block Inc are close in size by market cap, and Illumina, Inc. is trading nearer its 52-week high, Block Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Block Inc for 78 Days on average.
| ILMN | XYZ | |
|---|---|---|
Market Cap | $39.95B | $45.20B |
Volume | 3,169,503 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $293.69 | $84.85 |
52-Week Low | $91.00 | $49.04 |
Typical Hold Time | 83 Days | 78 Days |
Enterprise Value | $41.31B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Block (XYZ) trades at $77.09, up 1.34% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats but faces profitability challenges with a net margin of just 1.43%. Recent developments include expanding Square and Cash App partnerships with Apple and Workday, while pursuing a national trust bank charter to reduce third-party banking costs.
The stock offers 26% upside to the $97.47 consensus target with strong analyst support (77% buy ratings), though high P/E of 134.34 raises valuation concerns. Key risks include declining net income margins, insider selling activity, and competitive fintech pressures. The upcoming Q3 2026 earnings report on November 3rd will be critical for validating growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
